Table 1 Characteristics of included studies in the meta-analysis
References | Years | Study design | No. of cases | Location | Acquisition time | PCR type | Target gene | Diagnostic standard | Sensitivity (%) | Specificity (%) | Antibiotic treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|
[19] | 2010 | Prospective | 64 | Knee | Preoperative | RT-qPCR | 16S rRNA | M, H | 71 | 100 | Y |
[14] | 2018 | Prospective | 116 | Knee | Preoperative | PCR SEQ | 16S/18S rRNA | MSIS | 55.60 | 82 | N |
[20] | 2018 | Prospective | 114 | Hip, knee | Preoperative | PCR SEQ | 16S rRNA | MSIS | 71.40 | 98.50 | Y |
[21] | 2016 | Retrospective | 284 | Knee | Preoperative | PCR panel | Home designed primers | MSIS | 55.60 | 91.80 | Y |
2016 | Retrospective | 62 | Knee | Preoperative | PCR-ESI/MS | Specific primer | MSIS | 82.30 | 84.40 | Y | |
[22] | 2018 | Prospective | 87 | Hip, knee | Intraoperative | PCR SEQ | 16S rRNA | MSIS | 68.10 | 100 | NA |
[23] | 2018 | Prospective | 17 | Hip, knee | Preoperative | PCR lateral flow immunoassay | 16S rDNA (multiplex) | P, H, M | 87.50 | 100 | NA |
2018 | Prospective | 60 | Hip, knee | Preoperative | PCR lateral flow immunoassay | 16S rDNA (multiplex) | P, H, M | 82 | 89 | NA | |
[25] | 2018 | Prospective | 142 | Hip, knee | Preoperative | Multiplex PCR | Specific primer | EBJIS | 60 | 89 | N |
[24] | 2005 | Prospective | 92 | Hip, knee | Intraoperative | Broad-range PCR | Specific primer | P, M, R | 92 | 74 | N |
[13] | 2018 | Prospective | 214 | Hip, knee | Preoperative | RT-PCR | 16S/28S rRNA | ICM | 100 | 99.50 | N |
[18] | 2014 | Retrospective | 103 | Knee | NA | PCR-ESI/MS | Specific primer | MSIS | 81 | 95 | Y |
[17] | 2018 | Retrospective | 67 | Hip, knee | NA | RT BR-PCR | 16S rRNA | MSIS | 83 | 85.70 | N |